In this guide
What is Modified Citrus Pectin?
Pectin is a plant polysaccharide. Modified citrus pectin is processed to alter molecular size and solubility. Standard food pectin, named MCP products, MCP-alginate combinations and galectin-3 drug research are not interchangeable. [1], [4]
Typical Modified Citrus Pectin Protocols
| Source and question | Preparation | Amount each administration | Daily total | Frequency and duration | Main interpretation |
|---|---|---|---|---|---|
| Keizman 2021 · single-arm phase II · 60 enrolled, 59 evaluated at 6 months | PectaSol capsules | 4.8 g | 14.4 g/day | Three times daily for 6 months; extension for nonprogressors | PSA kinetics without a randomized comparator; no demonstrated survival benefit |
| Lau 2021 · 68 adults with hypertension randomized; 52 completed | PectaSol-C versus placebo | 4.8 g | 14.4 g/day | Three times daily for 6 months; 30 minutes before or 2 hours after food | No favorable between-group effect on primary collagen markers; unequal attrition |
- Exact product
- Record species, form, lot and co-ingredients.
- Each administration
- Keep amount, timing and context.
- Real endpoint
- Separate biomarker, symptom and clinical outcome.
What is it commonly used for?
Products are marketed for “detoxification” or galectin-3 effects. Current evidence does not establish clinically useful lead removal, cancer treatment or heart-failure prevention. The uncontrolled 2008 pediatric paper has an inaccessible erratum; its dosage and numerical findings are not used here. Five cases involving MCP alone or with alginate cannot isolate its effect. [1], [2]
The adult trials below address two different questions: PSA kinetics after biochemical prostate-cancer recurrence and fibrosis markers in people with hypertension. Those outcomes are not interchangeable. [3], [4]
One result answers one question
How do forms and labels differ?
Record the named modified pectin, molecular specification when supplied, each amount, daily total and whether alginate or other binders are present. Standard citrus pectin cannot inherit MCP trial results. [4], [5]
How should the product be stored?
Follow the finished product’s label, keep it dry in its original container and away from children. Discard an expired, heat-damaged, broken-seal or untraceable product.
What does human research show?
| Question | Direct evidence | Finding | Boundary |
|---|---|---|---|
| Fibrosis and hypertension | Lau: 68 randomized, 52 completed | No favorable between-group effect on primary collagen markers, vascular function or echocardiographic measures | Surrogate outcomes; no demonstrated heart-failure prevention |
| Biochemical prostate recurrence | Keizman: 60 enrolled, 59 evaluated at six months | 46/59 met a composite PSA-kinetics and imaging endpoint | No control group; not a cure rate or survival result |
| Lead | Uncontrolled pediatric paper and five cases | Clinical efficacy unestablished | Pediatric erratum not retrieved; some products combined |
Why does the hypertension trial matter?
Participants had treated hypertension and elevated galectin-3. They received 4.8 g three times daily for six months. Only 22 MCP participants and 30 placebo participants completed the study: more gastrointestinal discontinuations in the MCP arm left the groups unbalanced. There was no favorable effect on the primary collagen markers after adjustment for multiple comparisons. A change within one group is not evidence of a between-group benefit. EcoNugenics supplied the product and placebo. [4]
What does the prostate study’s 78% result mean?
In this open study, 46 of 59 evaluated men met a composite endpoint involving stable/decreased PSA and/or a longer PSA doubling time, with negative imaging. That does not mean 78% of cancers regressed. There was no randomized comparator and no established survival benefit. Mild bloating was reported in 12 of the 60 enrolled participants. EcoNugenics funded the study; one author disclosed being the developer of the sponsoring supplement company. [3]
Keep the finished product reviewable
What are the risks and interactions?
Gastrointestinal symptoms and allergy are possible, and pectin may alter absorption of oral medicines. Children, pregnancy, kidney disease, diagnosed metal toxicity and cancer require specialist care. Unapproved chelation products must not replace source control or established treatment. [2], [3], [5], [6]
Contact poison control or urgent clinical care for suspected lead or other toxic exposure, neurologic symptoms, severe abdominal pain, repeated vomiting or a child with possible ingestion. Do not delay prescribed cancer or toxicology care.
What is the legal and regulatory status?
In the United States, FDA does not approve dietary supplements for safety and effectiveness before marketing, and no over-the-counter chelation product is approved. In Canada, check the exact product’s NPN and authorized conditions of use in Health Canada’s database. A licence does not extend those indications to cancer or lead-poisoning treatment. [5], [7], [8]
When should use stop?
Stop for any allergic reaction, persistent symptom worsening, unexpected laboratory result or doubt about product identity.
What should be monitored?
Separate the goal: diagnosed lead exposure, PSA kinetics, galectin-3 research or bowel tolerance. Keep product, lot, administrations, medicines and validated clinical measurements together. Urinary excretion alone does not prove safer total body burden.
What can community experience add?
Reports can compare taste and gastrointestinal tolerance. They cannot establish metal clearance, cancer control or medicine absorption. No systematic current community sample was assembled.
How do related options compare?
| Option | Main distinction |
|---|---|
| Food pectin | Gelling fiber; not the studied modified product |
| Modified citrus pectin | Processed molecular profile; named products differ |
| MCP plus alginate | Combination evidence cannot isolate MCP |
Common questions
Does MCP treat lead poisoning?
That is not established. The pediatric study was uncontrolled and its erratum could not be reviewed. Lead poisoning requires removal of the exposure source and appropriate toxicology care. [1], [5]
What does 14.4 g/day mean?
It means 4.8 g three times daily in two adult trials of named products. It is not a recommended public dose or a pediatric dose. [3], [4]
Does MCP treat prostate cancer?
The evidence does not establish that. PSA-kinetics findings without a comparator do not demonstrate tumor regression or longer survival. [3]
What did the hypertension trial find?
No favorable between-group effect on its primary markers after six months. More discontinuations in the MCP arm also reduce certainty. [4]
Is ordinary food pectin equivalent?
No. Ordinary dietary fiber, modified pectin and an alginate combination need not have the same composition or evidence. [2], [4]
What should I record for a consultation?
The exact product, lot, amount each administration, medicines, gastrointestinal tolerance and clinician-requested measurements. A log does not replace oncology or toxicology follow-up.
Glossary
Terms for reading the evidence.
- Endpoint
- A defined result measured in a study.
- Anaphylaxis
- A potentially life-threatening systemic allergic reaction.
- Biomarker
- A biological measure that does not guarantee clinical benefit.
- Standardization
- A measured specification for a product component.
- Cross-reactivity
- Immune recognition of related proteins from different sources.
How this guide was researched
NCBI identities, publication notices, indexed abstracts and available open methods were checked. Null outcomes, mixed products, surrogate endpoints and missing details remain visible.
Research record · checked October 9, 2026
Access: the full Keizman (PMC8706421) and Lau (PMC7838053) articles were read, including methods, results, attrition and funding disclosures.
Inaccessible erratum: PMID 18616067 indexes an erratum in Altern Ther Health Med 2008;14(6):18. Its text could not be retrieved from the public sources consulted. Pediatric dosage and numerical effects from that paper are therefore not used in this guide.
Limits: PSA kinetics, galectin-3 and urinary excretion are not evidence of cure, survival or clinically effective lead removal.
Explore the sources
Primary human evidence and official context.
Showing 8 sources
- 01
The role of modified citrus pectin as an effective chelator of lead in children hospitalized with toxic lead levels. ↗
Uncontrolled pediatric clinical study
Uncontrolled pediatric study. Indexed erratum: 2008;14(6):18; notice text not retrieved. No dosage or numerical effect estimate used here.
- 02
Integrative medicine and the role of modified citrus pectin/alginates in heavy metal chelation and detoxification--five case reports. ↗
Five case reports
Five cases of MCP alone or with alginate; no causal attribution possible.
- 03
Modified Citrus Pectin Treatment in Non-Metastatic Biochemically Relapsed Prostate Cancer: Results of a Prospective Phase II Study. ↗
Prospective single-arm phase II study
Full text read: 60 enrolled, 59 evaluated at six months; 4.8 g three times daily. Uncontrolled composite PSA endpoint; industry funding disclosed.
- 04
Galectin-3 Inhibition With Modified Citrus Pectin in Hypertension. ↗
Randomized placebo-controlled proof-of-concept trial
Full text read: 68 randomized, 52 completed; 4.8 g three times daily for six months. Null primary findings and unequal attrition.
- 05
Questions and Answers on Unapproved Chelation Products ↗
Official safety warning
FDA states that no over-the-counter chelation product is approved and warns that unapproved products can delay effective care.
- 06
Modified Citrus Pectin Supplement ↗
Clinical-trial intervention listing
Lists disease-specific research without establishing cancer prevention, treatment or survival benefit.
- 07
Information for Consumers on Using Dietary Supplements ↗
Official regulatory overview
FDA does not approve supplements for safety and effectiveness before marketing.
- 08
Licensed Natural Health Products Database (LNHPD) ↗
Official product database
An NPN identifies a licensed product; verify its indication, ingredients and risk information.
No matching sources
Try a different term or show the full list.
Editorial note
This guide separates composition, biomarker, symptom and clinical outcome. It does not turn a narrow signal into a general promise.